BioNTech SE ADR (NASDAQ: BNTX) on Monday, soared 3.82% from the previous trading day, before settling in for the closing price of $115.79. Within the past 52 weeks, BNTX’s price has moved between $76.53 and $131.49.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 1058.90%. The company achieved an average annual earnings per share of -180.38%. With a float of $239.44 million, this company’s outstanding shares have now reached $239.74 million.
The extent of productivity of a business whose workforce counts for 3082 workers is very important to gauge. In terms of profitability, gross margin is 84.31%, operating margin of -30.81%, and the pretax margin is -10.38%.
BioNTech SE ADR (BNTX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of BioNTech SE ADR is 0.13%, while institutional ownership is 19.50%. The most recent insider transaction that took place on Dec 13 ’24, was worth 601,398. Before that another transaction happened on Dec 11 ’24, when Company’s 10% Owner proposed sale 22,450 for $116.85, making the entire transaction worth $2,623,283.
BioNTech SE ADR (BNTX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.89 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -180.38% per share during the next fiscal year.
BioNTech SE ADR (NASDAQ: BNTX) Trading Performance Indicators
BioNTech SE ADR (BNTX) is currently performing well based on its current performance indicators. A quick ratio of 7.21 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.73. Likewise, its price to free cash flow for the trailing twelve months is 19.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.15, a number that is poised to hit 0.46 in the next quarter and is forecasted to reach -3.39 in one year’s time.
Technical Analysis of BioNTech SE ADR (BNTX)
The latest stats from [BioNTech SE ADR, BNTX] show that its last 5-days average volume of 0.49 million was inferior to 0.54 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 85.34%. Additionally, its Average True Range was 4.13.
During the past 100 days, BioNTech SE ADR’s (BNTX) raw stochastic average was set at 76.99%, which indicates a significant decrease from 89.53% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.45% in the past 14 days, which was lower than the 50.48% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $113.20, while its 200-day Moving Average is $99.25. Now, the first resistance to watch is $122.42. This is followed by the second major resistance level at $124.64. The third major resistance level sits at $127.81. If the price goes on to break the first support level at $117.03, it is likely to go to the next support level at $113.86. Assuming the price breaks the second support level, the third support level stands at $111.64.
BioNTech SE ADR (NASDAQ: BNTX) Key Stats
Market capitalization of the company is 28.82 billion based on 239,740K outstanding shares. Right now, sales total 4,133 M and income totals 1,007 M. The company made 1,369 M in profit during its latest quarter, and 217,830 K in sales during its previous quarter.
